AbbVie (NYSE:ABBV) Posts Earnings Results, Misses Expectations By $0.36 EPS

Key Points

• AbbVie reported Q1 adjusted EPS of $2.65, missing consensus by $0.36, but revenue rose ~12% to about $15 billion and management raised full‑year adjusted EPS guidance to $14.08–$14.28.
• SKYRIZI and RINVOQ powered the quarter (roughly $4.5B and $2.1B respectively) with strong growth and a bullish 2026 outlook, while pipeline progress included a U.S. Crohn’s submission for subcutaneous SKYRIZI; conversely, the FDA issued a complete response letter for TrenibotE on manufacturing grounds.
• Management declared a quarterly dividend of $1.73 (3.4% yield) despite a high payout ratio (~293%), the stock traded up after the print, and AbbVie retains a stretched valuation (PE ~86.7).

AbbVie (NYSE:ABBV - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $2.65 EPS for the quarter, missing analysts' consensus estimates of $3.01 by ($0.36), FiscalAI reports. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. During the same quarter in the previous year, the firm posted $2.46 EPS. The firm's quarterly revenue was up 12.4% compared to the same quarter last year.

Here are the key takeaways from AbbVie's conference call:

• AbbVie beat Q1 expectations with adjusted EPS of $2.65 and $15 billion in revenues, and raised full‑year adjusted EPS guidance by $0.12 to $14.08–$14.28, citing stronger-than-expected demand across the portfolio.
• Immunology momentum remains a key driver—SKYRIZI sales were $4.5B (up ~29% operationally) and management now models ~$21.6B for 2026, while RINVOQ reached $2.1B (up ~20%) with a $10.2B full‑year assumption, both outperforming expectations.
• Pipeline progress in gastroenterology was highlighted—subcutaneous induction SKYRIZI for Crohn’s was submitted in the U.S. with an approval decision expected later this year, and a combo of SKYRIZI + ABBV‑382 showed ~42% endoscopic remission at week 24 in a highly refractory cohort, suggesting potentially transformational efficacy.
• Early-stage R&D catalysts include encouraging obesity data for the long‑acting amylin analog ABBV‑295 (~10% weight loss in 12 weeks, good tolerability) and an accelerated oncology plan with etentamig now expected to be submitted by year‑end, both cited as near‑term growth opportunities.
• The FDA issued a complete response letter for TrenibotE due to manufacturing questions (no safety/efficacy issues), delaying a U.S. approval path while international launches are still expected later this year.

AbbVie Stock Performance

Shares of AbbVie stock traded up $6.83 on Wednesday, hitting $204.52. 7,178,072 shares of the company's stock were exchanged, compared to its average volume of 7,161,787. The company has a 50-day simple moving average of $215.29 and a 200-day simple moving average of $221.79. The stock has a market capitalization of $361.62 billion, a PE ratio of 86.71, a PEG ratio of 0.71 and a beta of 0.38. AbbVie has a 1 year low of $176.57 and a 1 year high of $244.81.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 293.22%.

Insider Buying and Selling at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of Jackson Hole Trust boosted its stake in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock worth $1,648,000 after acquiring an additional 44 shares during the last quarter. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.3% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after acquiring an additional 45 shares during the last quarter. one8zero8 LLC boosted its stake in shares of AbbVie by 0.5% during the 4th quarter. one8zero8 LLC now owns 9,825 shares of the company's stock worth $2,245,000 after acquiring an additional 50 shares during the last quarter. Papamarkou Wellner Asset Management inc. boosted its stake in shares of AbbVie by 0.5% during the 4th quarter. Papamarkou Wellner Asset Management inc. now owns 9,611 shares of the company's stock worth $2,196,000 after acquiring an additional 52 shares during the last quarter. Finally, Twin Focus Capital Partners LLC boosted its stake in shares of AbbVie by 5.6% during the 4th quarter. Twin Focus Capital Partners LLC now owns 1,082 shares of the company's stock worth $247,000 after acquiring an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 27th. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Morgan Stanley increased their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Barclays assumed coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an "overweight" rating and a $275.00 price objective on the stock. Finally, Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.19.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 revenue beat and guidance raise — AbbVie reported ~$15.00B in Q1 revenue (up ~12%) and raised 2026 adjusted EPS guidance to $14.08–$14.28, signaling stronger-than-expected top-line momentum that supports upside. AbbVie Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Blockbuster immunology growth — Skyrizi and Rinvoq together generated over $6.6B in the quarter (Skyrizi ~$4.48B; Rinvoq ~$2.12B), far outpacing Humira (~$688M) and showing the portfolio transition is working. AbbVie beats Q1 2026 earnings, raises full-year forecast
• Positive Sentiment: Regulatory and pipeline catalysts — AbbVie filed for an expanded Rinvoq label in alopecia areata based on positive Phase III data and struck a strategic option/deal around KRAS assets (Kestrel), both of which add near‑ and medium‑term upside case for revenue and M&A optionality. ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata
• Neutral Sentiment: Partnership & R&D updates — Small‑cap partners (EvolveImmune milestone, Kestrel option) and planned research campus support R&D depth but are longer‑term value drivers rather than immediate earnings levers. EvolveImmune Therapeutics milestone
• Neutral Sentiment: Dividend and capital allocation steady — Commentary and coverage remind investors AbbVie maintains a strong dividend and cash flow profile, supporting income investors even amid share‑price swings. AbbVie Maintains Dividend Strength
• Negative Sentiment: Legacy declines and mixed headlines — Humira and Imbruvica revenue continue to decline; some coverage notes "negative sentiment" and intraday yo‑yo trading despite the immunology beat, which can cap multiple expansion. AbbVie Flails As 'Negative Sentiment' Persists
• Negative Sentiment: EPS metric noise and valuation — Adjusted EPS guidance was lifted, but different outlets flagged small misses or variations versus some analyst models and AbbVie still trades with a high P/E relative to its growth profile, which may keep volatility elevated. MarketBeat earnings summary

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.